1. Home
  2. CSBR vs ACTU Comparison

CSBR vs ACTU Comparison

Compare CSBR & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSBR
  • ACTU
  • Stock Information
  • Founded
  • CSBR 1985
  • ACTU 2015
  • Country
  • CSBR United States
  • ACTU United States
  • Employees
  • CSBR N/A
  • ACTU N/A
  • Industry
  • CSBR Biotechnology: Biological Products (No Diagnostic Substances)
  • ACTU
  • Sector
  • CSBR Health Care
  • ACTU
  • Exchange
  • CSBR Nasdaq
  • ACTU NYSE
  • Market Cap
  • CSBR 113.0M
  • ACTU 135.0M
  • IPO Year
  • CSBR 1986
  • ACTU 2024
  • Fundamental
  • Price
  • CSBR $7.97
  • ACTU $8.00
  • Analyst Decision
  • CSBR Strong Buy
  • ACTU Strong Buy
  • Analyst Count
  • CSBR 1
  • ACTU 1
  • Target Price
  • CSBR $12.00
  • ACTU $20.00
  • AVG Volume (30 Days)
  • CSBR 40.8K
  • ACTU 42.0K
  • Earning Date
  • CSBR 03-11-2025
  • ACTU 05-21-2025
  • Dividend Yield
  • CSBR N/A
  • ACTU N/A
  • EPS Growth
  • CSBR N/A
  • ACTU N/A
  • EPS
  • CSBR 0.46
  • ACTU N/A
  • Revenue
  • CSBR $58,591,000.00
  • ACTU N/A
  • Revenue This Year
  • CSBR $15.11
  • ACTU N/A
  • Revenue Next Year
  • CSBR $7.80
  • ACTU N/A
  • P/E Ratio
  • CSBR $17.42
  • ACTU N/A
  • Revenue Growth
  • CSBR 19.03
  • ACTU N/A
  • 52 Week Low
  • CSBR $3.60
  • ACTU $5.51
  • 52 Week High
  • CSBR $11.99
  • ACTU $11.73
  • Technical
  • Relative Strength Index (RSI)
  • CSBR 43.19
  • ACTU N/A
  • Support Level
  • CSBR $7.80
  • ACTU N/A
  • Resistance Level
  • CSBR $8.43
  • ACTU N/A
  • Average True Range (ATR)
  • CSBR 0.78
  • ACTU 0.00
  • MACD
  • CSBR 0.01
  • ACTU 0.00
  • Stochastic Oscillator
  • CSBR 42.86
  • ACTU 0.00

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

About ACTU ACTUATE THERAPEUTICS INC

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Share on Social Networks: